NexImmune (7370) Stock Price & Analysis
7370 Stock Chart & Stats
- Day’s Range
- EUR 3.30 - EUR 3.30
- 52-Week Range
- EUR 3.30 - EUR 3.30
- Previous Close
- EUR 3.30
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 124
- Enterprise Value
- EUR 1.37M
- Total Cash (Recent Filing)
- EUR 2.42M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- 0.0
- Beta
- N/A
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Technology
NexImmune's AIM technology offers a unique approach to immunotherapy, potentially differentiating it in the competitive biotech space.
Partnership Opportunities
Collaborations with larger pharmaceutical companies can provide capital and resources, aiding in product development and market entry.
Low Leverage
A low leverage position provides financial flexibility and reduces risk, allowing NexImmune to potentially withstand financial challenges better.
Bears Say
Lack Of Revenue
The absence of revenue indicates challenges in commercializing products, which could hinder long-term financial sustainability and growth.
Consistent Losses
Ongoing losses suggest operational inefficiencies and the need for strategic adjustments to achieve profitability and sustain operations.
Negative Cash Flow
Negative cash flow challenges liquidity and sustainability, necessitating improved cash management or external funding to maintain operations.
7370 FAQ
What was NexImmune’s price range in the past 12 months?
What is NexImmune’s market cap?
When is NexImmune’s upcoming earnings report date?
How were NexImmune’s earnings last quarter?
Is NexImmune overvalued?
Does NexImmune pay dividends?
What is NexImmune’s EPS estimate?
How many shares outstanding does NexImmune have?
What happened to NexImmune’s price movement after its last earnings report?
Which hedge fund is a major shareholder of NexImmune?
What is the TipRanks Smart Score and how is it calculated?
Company Description
NexImmune
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Craig R. Jalbert
- Employees
- 6
- Website
- www.neximmune.com
- Address
- 9119 Gaither Road, Gaithersburg, MD, 20877, US
NexImmune (7370) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 4 |
| Technical Analysis | 1 | 1 | 0 |
| Moving Averages | 4 | 4 | 4 |
